7 results about "Nevirapine" patented technology

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The invention discloses application of a pathogenic transposon element pL1HS as a lung squamous cell carcinoma biomarker and a treatment target. The 5 '-UTR region of the pathogenic transposon element pL1HS disclosed by the invention has a nucleic acid sequence as shown in SEQ ID NO.1, and specific detection primers of the pathogenic transposon element pL1HS are respectively as shown in SEQ ID NO.2 and SEQ ID NO.3. Animal experiments prove that the growth of lung squamous cell carcinoma can be remarkably inhibited by combined application of the nevirapine as a reverse transcription and transposition inhibitor and the cGAS inhibitor. The pathogenic transposon element pL1HS can be used as a novel molecular marker in the diagnosis application dimension, and provides accurate detection indexes for early screening, pathological typing and prognosis of lung squamous cell carcinoma; in the aspect of treatment application, a new direction is developed for a targeted intervention strategy of pL1HS, especially a combined medication scheme of a multi-channel inhibitor.

The present invention discloses a pharmaceutical composition containing homoharringtonine and its application in the preparation of anti-HIV viral drugs. The pharmaceutical composition is composed of homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor. The nucleoside reverse transcriptase inhibitor is selected from one of the compounds zidovudine, lamivudine, and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds nevirapine, efavirenz, and rilpivirine. The pharmaceutical composition has a significant synergistic effect in treating HIV, improves the efficacy of the drug, reduces the dosage of a single drug, reduces toxic side effects, and can significantly inhibit the production of viruses in combination, producing a very significant antiviral effect, and improving the current status of the treatment of HIV-1, especially middle and late stage AIDS.

The application relates to an HIV-1 latent infection activator, a medicine and purposes. An HIV-1 latent infection activator comprises ISX-9 and / or ML327. The HIV-1 latent infection activator further comprises an HDAC inhibitor and / or a BET inhibitor. The HDAC inhibitor is quinostat. The BET inhibitor is birabresib or AZD5153. A medicine comprises the HIV-1 latent infection activator and an HIV-1 inhibitor. The HIV-1 inhibitor is a polypeptide EKL1C, and the amino acid sequence is shown in SEQ ID NO:1. The HIV-1 inhibitor comprises one or more of zidovudine, nevirapine or indinavir. The HIV-1 latent infection activator provided by the application can activate latent HIV, and is a new safe and efficient HIV-1 latent infection activator.

The invention relates to an aza-alicyclic ring substituted pyrimidine derivative and a preparation method thereof, the aza-alicyclic ring substituted pyrimidine derivative has a structure as shown in a formula I. The aza-alicyclic ring substituted pyrimidine derivative provided by the invention is novel in structure, most of the compounds show relatively strong anti-HIV-1 activity, and the EC50 value is between 9.40 nM and 238 nM. Wherein the activity of compounds WP-10a (EC50 is equal to 12.6 + / -0.68 nM), WP-10b (EC50 is equal to 9.40 + / -0.96 nM), WP-10c (EC50 is equal to 18.3 + / -1.6 nM) and WP-10d (EC50 is equal to 26.2 + / -6.0 nM) of which the X site is substituted by amino azetidine is particularly prominent, the WP-10b with the optimal activity has the antiviral effect of single-digit nanomole, the activity is improved by about 30 times compared with that of a drug nevirapine (EC50 is equal to 281 + / -38.7 nM) on the market, and the activity is equivalent to that of efavirenz (EC50 is equal to 5.20 + / -0.90 nM)

The invention relates to a carbonyl-substituted pyrimidine derivative as well as a preparation method and application thereof, and belongs to the technical field of organic compound synthesis and medical application. The carbonyl-substituted pyrimidine derivative has a structure as shown in a formula I. The carbonyl-substituted pyrimidine derivative disclosed by the invention is novel in structure and shows good anti-HIV-1 activity as an HIV-1 inhibitor, and the EC50 value of the carbonyl-substituted pyrimidine derivative ranges from 4.28 nM to 274 nM and is obviously superior to that of a drug nevirapine (EC50 = 281 + / -38.7 nM) on the market.

The invention relates to the field of food detection, in particular to an analysis and detection method for antiviral drug residues in eggs, which comprises the following steps: S1, sample pretreatment: 1.1, sample preparation: shelling eggs, homogenizing, and storing at 4 DEG C; 1.2, extracting: weighing a homogenate sample, extracting twice by using 90% acetonitrile-1% formic acid solution, and merging supernate; 1.3, purifying and redissolving: purifying the supernate through an EMR-Lipid solid-phase extraction column, collecting eluent, blowing the eluent to be nearly dry at 40 DEG C by nitrogen, redissolving by using a formic acid-methanol solution, and filtering to obtain a matrix extracting solution; s2, preparing a standard solution; s3, instrument detection: performing chromatography-tandem mass spectrometry detection; s4, quantitative analysis: calculating the residual quantity of the eight antiviral drugs in the eggs according to the quantitative ion peak area by adopting a matrix matching standard curve external standard method. The precise detection of eight viruses, namely nevirapine, peramivir, famciclovir, rimantadine, amantadine, oseltamivir, imiquimod and memantine, is realized.